Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Inebilizumab

EU orphan designation number: EU/3/17/1856   
Active ingredient: Inebilizumab
Indication: Treatment of neuromyelitis optica spectrum disorders
Sponsor: AstraZeneca AB
SE-151 85 Södertälje, Sverige

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/03/2017 Orphan designation EMA/OD/267/16 (2017)1984 of 20/03/2017